Well StudiedWeight LossGrowth Hormone

CJC-1295 (without DAC)

Modified GRF 1-29

Short-Acting Growth Hormone Releasing Hormone Analog

Half-life

30 minutes - 2 hours

Chain length

Not reported

Reference frequency

2-3 times daily (morning, post-workout optional, bedtime)

Research overview

DoseGear research brief

Synthetic growth hormone releasing hormone analog with short half-life enabling pulsatile GH secretion patterns resembling natural physiology. Unlike CJC-1295 with DAC, this version preserves natural GH pulsatility without continuous elevation.

Mechanism of action

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Short-acting modified GHRH analog without the albumin-binding DAC modification.

What it is researched for

Pituitary growth-hormone-release research through GHRH-receptor stimulation.

Research observation window

Not reported for the without-DAC product. Long-duration CJC-1295 evidence concerns the albumin-binding compound.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
Anti-Aging/Wellness	100mcg	2x daily (morning and bedtime)	SubQ
Body Composition	100-150mcg	3x daily (morning, post-workout, bedtime)	SubQ
Maximum GH Release	200mcg	2-3x daily with GHRP	SubQ
Sleep Enhancement	100-200mcg	Once at bedtime	SubQ

Reference cycle

12-16 weeks

Reference storage

Lyophilized: 2-8°C refrigerated; Reconstituted: 2-8°C refrigerated, use within 30 days

Safety context

Reported side effects

Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)

Contraindications & cautions

Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding

Scientific references

01
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
Scientific citationHuman growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology (2005).
02
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Scientific citationProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism (2006).
03
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Scientific citationPulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism (2006).
04
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
Scientific citationOnce-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism (2006).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Growth Hormone